5 Stocks Pushing The Health Services Industry Higher
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelAll three major indices are trading up today with the Dow Jones Industrial Average (^DJI) trading up 62 points (0.4%) at 14,518 as of Thursday, March 14, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,808 issues advancing vs. 1,087 declining with 143 unchanged.The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Health Management Associates (HMA), up 3.2%, Community Health Systems (CYH), up 2.4%, Smith & Nephew (SNN), up 2.5%, Fresenius Medical Care Corporation (FMS), up 1.1% and DaVita HealthCare Partners (DVA), up 0.9%. A company within the industry that fell today was Edwards Life (EW), up 1.2%.TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:5. Quest Diagnostics (DGX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Quest Diagnostics is up $0.68 (1.2%) to $56.66 on average volume Thus far, 607,869 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $55.85-$56.73 after having opened the day at $56.13 as compared to the previous trading day's close of $55.99. Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $8.9 billion and is part of the health care sector. The company has a P/E ratio of 14.3, below the S&P 500 P/E ratio of 17.7. Shares are down 3.9% year to date as of the close of trading on Wednesday. Currently there is 1 analyst that rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 14 rate it a hold.TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE
Latest Headlines about HCA
-
7 Smaller-Company Stocks to Withstand a Possible Correction
11:28AM 03/15/13
-
Top Insider Trades: HCA, TWO, LYB, ST
09:21AM 02/21/13
-
Stocks Mixed; Dow Closes Above 14,000
04:33PM 02/12/13
-
Stock Futures Flat Ahead of Obama Speech; Coke Falls
09:04AM 02/12/13
-
Top Insider Trades: HCA RFP HTZ HRG
11:02AM 12/19/12
-
'Mad Money' Lightning Round: Stay Away From Groupon
06:00AM 12/19/12
-
Cramer's 'Mad Money' Recap: Get in the Game Now
07:39PM 12/18/12
Latest from TheStreet Wire
-
Newell Rubbermaid Stock Hits New 52-Week High (NWL)
02:29PM 05/20/13
-
Sohu.com Stock Hits New 52-Week High (SOHU)
02:00PM 05/20/13
-
Dow Today: Alcoa (AA) Higher
02:00PM 05/20/13
-
Carter's Stock Hits New 52-Week High (CRI)
01:20PM 05/20/13
-
5 Stocks Underperforming Today In The Drugs Industry
01:04PM 05/20/13
-
SRCL, FAST, LEN, CX And PHM, Pushing Materials & Construction Industry Downward
01:04PM 05/20/13
-
5 Stocks Pushing The Banking Industry Downward
01:04PM 05/20/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
